Abstract

Review question
  • Primary objective: To determine whether Hib conjugate vaccines reduce Hib mortality and morbidity in paediatric (aged under 18 years) and adult (aged 18 years and over) patients with SCD.
  • Secondary objectives: To assess the immunogenicity of Hib conjugate vaccines in paediatric and adult patients affected with SCD. To assess the safety of Hib conjugate vaccines in paediatric and adult patients affected with SCD. To determine any variation in effect according to type of vaccine, mode of administration (separately or in combination with other vaccines), number of doses, and age at first dose.
Haemophilus influenzae type B